PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-2.48%
Negative revenue growth while ACB.TO stands at 0.12%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-18.23%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-61.11%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-61.11%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-205.02%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-181.58%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-181.58%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
9.00%
Share reduction more than 1.5x ACB.TO's 38.04%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
9.00%
Diluted share reduction more than 1.5x ACB.TO's 43.02%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-102.79%
Negative OCF growth while ACB.TO is at 42.05%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
65.09%
FCF growth above 1.5x ACB.TO's 38.25%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
998.76%
5Y CAGR of 998.76% while ACB.TO is zero. Bruce Berkowitz would see if small improvements can scale into a larger advantage.
70.17%
3Y revenue/share CAGR above 1.5x ACB.TO's 13.92%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
99.10%
Positive long-term OCF/share growth while ACB.TO is negative. John Neff would see a structural advantage in sustained cash generation.
-100.92%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
99.69%
Positive 3Y OCF/share CAGR while ACB.TO is negative. John Neff might see a big short-term edge in operational efficiency.
-3992.18%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-2769.45%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-171.89%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
3001.42%
10Y equity/share CAGR above 1.5x ACB.TO's 964.93%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
191.30%
Below 50% of ACB.TO's 2496.50%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-26.97%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13.91%
Firm’s AR is declining while ACB.TO shows 3.41%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-0.89%
Inventory is declining while ACB.TO stands at 8.71%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
1.70%
Asset growth at 50-75% of ACB.TO's 2.64%. Martin Whitman questions if the firm is lagging expansions or if the competitor invests more aggressively.
-24.79%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
72.83%
We have some new debt while ACB.TO reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
-42.29%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
39.21%
We expand SG&A while ACB.TO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.